Logotipo del repositorio
Logotipo del repositorio
 

Etelcalcetide and Paricalcitol in Chronic Kidney Disease: When the Target Is Inflammation

Vista sencilla de ítem
datacite.rightshttp://purl.org/coar/access_right/c_abf2spa
dc.contributor.authorD’Marco, Luis
dc.contributor.authorCheca-Ros, Ana
dc.contributor.authorGamero, Dionilux
dc.contributor.authorSoto, Carlos
dc.contributor.authorSalazar, Juan
dc.contributor.authorNava, Manuel
dc.contributor.authorBermúdez, Valmore
dc.contributor.authorDapana, Fabiola
dc.date.accessioned2023-08-30T18:12:30Z
dc.date.available2023-08-30T18:12:30Z
dc.date.issued2022
dc.description.abstractIntroduction: secondary hyperparathyroidism (SHP) is frequent in patients with chronic kidney disease (CKD), particularly in those in dialysis. To treat this complication, the current options available include phosphorus restriction, phosphate binders, the inhibition of parathyroid hormone (PTH) synthesis and secretion by the supplementation of vitamin D or VDR activators, or the use of calcimimetics. Beyond the control of PTH, the effects of the treatment of SHP on other biomarkers of risk may represent an additional benefit for this population. In this study, we explore the benefits of current SHP treatment options, mainly paricalcitol and/or etelcalcetide in the inflammatory state of hemodialysis (HD) patients. Results: the study finally included 142 maintenance HD patients (5 patients were excluded) followed for 6 months (dialysis vintage 26 30 months, mean age 70 years old, 73% women, 81% Spanish white, 47% diabetic). In this case, 52 patients were on regular treatment with paricalcitol for SHP and 25 patients were eligible to initiate etelcalcetide. The baseline serum levels of Ca, P, PTH, Ferritin, albumin, C-reactive protein (CRP), and other variables were measured. We found serum PTH levels showed an improvement after the treatment with etelcalcetide again paricalcitol and no treatment (p < 0.04). Of note, serum levels of CRP were significantly lower in a small group of patients (n = 11) receiving paricalcitol + etelcalcetide compared to paricalcitol or etelcalcetide alone. The proportion of patients with CRP within target ranges ( 1.0 mg/dL) increased significantly after combined treatment (p < 0.001). Conclusions: etelcalcetide proved to safely reduce the PTH levels without significant adverse events and the possibility of a synergic anti-inflammatory effect with the simultaneous use of Paricalcitol in HD patients.spa
dc.format.mimetypepdfspa
dc.identifier.citationD’Marco, L.; Checa-Ros, A.; Gamero, D.; Soto, C.; Salazar, J.; Nava, M.; Bermúdez, V.; Dapena, F. Etelcalcetide and Paricalcitol in Chronic Kidney Disease: When the Target Is Inflammation. Healthcare 2023, 11, 72. https://doi.org/ 10.3390/healthcare11010072spa
dc.identifier.doihttps://doi.org/10.3390/healthcare11010072
dc.identifier.issn22279032
dc.identifier.urihttps://hdl.handle.net/20.500.12442/13230
dc.language.isoengspa
dc.publisherMDPIspa
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.accessrightsinfo:eu-repo/semantics/openAccessspa
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.sourceHealthcareeng
dc.sourceVol. 11 No. 72 (2023)
dc.subjectcalcimimetics; vitamin D analogs; chronic kidney disease; inflammationspa
dc.titleEtelcalcetide and Paricalcitol in Chronic Kidney Disease: When the Target Is Inflammationspa
dc.type.driverinfo:eu-repo/semantics/articlespa
dc.type.spaArtículo científicospa
dcterms.referencesTorres, P.A.U.; De Broe, M. Calcium-Sensing Receptor, Calcimimetics, and Cardiovascular Calcifications in Chronic Kidney Disease. Kidney Int. 2012, 82, 19–25. [eng
dcterms.referencesLevin, A.; Bakris, G.L.; Molitch, M.; Smulders, M.; Tian, J.; Williams, L.A.; Andress, D.L. Prevalence of Abnormal Serum Vitamin D, PTH, Calcium, and Phosphorus in Patients with Chronic Kidney Disease: Results of the Study to Evaluate Early Kidney Disease. Kidney Int. 2007, 71, 31–38.eng
dcterms.referencesHerzog, C.A.; Asinger, R.W.; Berger, A.K.; Charytan, D.M.; Díez, J.; Hart, R.G.; Eckardt, K.-U.; Kasiske, B.L.; McCullough, P.A.; Passman, R.S.; et al. Cardiovascular Disease in Chronic Kidney Disease. A Clinical Update from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2011, 80, 572–586eng
dcterms.referencesEidman, K.E.;Wetmore, J.B. Treatment of secondary hyperparathyroidism: How do cinacalcet and etelcalcetide differ? Semin. Dial. 2018, 31, 440–444.eng
dcterms.referencesBrown, A.J.; Dusso, A.S.; Slatopolsky, E. Vitamin D analogs for Secondary Hyperparathyroidism. Nephrol. Dial. Transplant. 2002, 17 (Suppl.1), 10–19.eng
dcterms.referencesHu, X.; Shang, J.; Yuan, W.; Zhang, S.; Jiang, Y.; Zhao, B.; Duan, Y.; Xiao, J.; Zhao, Z. Effects of Paricalcitol on Cardiovascular Outcomes and Renal Function in Patients with Chronic Kidney Disease: A Meta-Analysis. Herz 2018, 43, 518–528.eng
dcterms.referencesBrickman, A.S.; Hartenbower, D.L.; Norman, A.W.; Coburn, J.W. Actions of 1 Alpha-Hydroxyvitamin D3 and 1,25- Dihydroxyvitamin D3 on Mineral Metabolism in Man. I. Effects on Net Absorption of Phosphorus. Am. J. Clin. Nutr. 1977, 30, 1064–1069.eng
dcterms.referencesBlock, G.A.; Chertow, G.M.; Sullivan, J.T.; Deng, H.; Mather, O.; Tomlin, H.; Serenko, M. An Integrated Analysis of Safety and Tolerability of Etelcalcetide in Patients Receiving Hemodialysis with Secondary Hyperparathyroidism. PLoS ONE 2019, 14, e0213774.eng
dcterms.referencesFriedl, C.; Zitt, E. Role of Etelcalcetide in the Management of Secondary Hyperparathyroidism in Hemodialysis Patients: A Review on Current Data and Place in Therapy. Drug Des. Dev. Ther. 2018, 12, 1589–1598eng
dcterms.referencesChennasamudram, S.P.; Noor, T.; Vasylyeva, T.L. Comparison of Sevelamer and Calcium Carbonate on Endothelial Function and Inflammation in Patients on Peritoneal Dialysis. J. Ren. Care 2013, 39, 82–89eng
dcterms.referencesKo, S.M.; Zhang, C.; Chen, Z.; D’Marco, L.; Bellasi, A.; Stillman, A.E.; Block, G.; Raggi, P. Epicardial Adipose Tissue Volume Increase in Hemodialysis Patients Treated with Sevelamer or Calcium-Based Phosphate Binders: A Substudy of the Renagel in New Dialysis Trial. J. Nephrol. 2016, 29, 683–690.eng
dcterms.referencesKoiwa, F.; Yokoyama, K.; Fukagawa, M.; Akizawa, T. Evaluation of Changes in Ferritin Levels during Sucroferric Oxyhydroxide Treatment. Clin. Kidney J. 2018, 12, 294–299.eng
dcterms.referencesOtsuki, T.; Utsunomiya, K.; Moriuchi, M.; Horikoshi, S.; Okamura, M.; Suzuki, H.; Okamura, M.; Maruyama, N.; Shibahara, N.; Abe, M. Effect of Sucroferric Oxyhydroxide on Fibroblast Growth Factor 23 Levels in Hemodialysis Patients. Nephron 2018, 140, 161–168.eng
dcterms.referencesChang, Y.-M.; Tsai, S.-C.; Shiao, C.-C.; Liou, H.-H.; Yang, C.-L.; Tung, N.-Y.; Hsu, K.-S.; Chen, I.-L.; Liu, M.-C.; Kao, J.-L.; et al. Effects of Lanthanum Carbonate and Calcium Carbonate on Fibroblast Growth Factor 23 and Hepcidin Levels in Chronic Hemodialysis Patients. Clin. Exp. Nephrol. 2016, 21, 908–916eng
dcterms.referencesChang, Y.-M.; Tsai, S.-C.; Shiao, C.-C.; Liou, H.-H.; Yang, C.-L.; Tung, N.-Y.; Hsu, K.-S.; Chen, I.-L.; Liu, M.-C.; Kao, J.-L.; et al. Effects of Lanthanum Carbonate and Calcium Carbonate on Fibroblast Growth Factor 23 and Hepcidin Levels in Chronic Hemodialysis Patients. Clin. Exp. Nephrol. 2016, 21, 908–916eng
dcterms.referencesRojas-Rivera, J.; De La Piedra, C.; Ramos, A.; Ortiz, A.; Egido, J. The Expanding Spectrum of Biological Actions of Vitamin D. Nephrol. Dial. Transplant. 2010, 25, 2850–2865.eng
dcterms.referencesSkaaby, T.; Husemoen, L.L.N.; Thuesen, B.H.; Pisinger, C.; Jørgensen, T.; Roswall, N.; Larsen, S.C.; Linneberg, A. Prospective Population-Based Study of the Association between Serum 25-Hydroxyvitamin-D Levels and the Incidence of Specific Types of Cancer. Cancer Epidemiol. Biomark. Prev. 2014, 23, 1220–1229eng
dcterms.referencesAnderson, J.L.; May, H.T.; Horne, B.D.; Bair, T.L.; Hall, N.L.; Carlquist, J.F.; Lappé, D.L.; Muhlestein, J.B.; Intermountain Heart Collaborative (IHC) Study Group. Relation of Vitamin D Deficiency to Cardiovascular Risk Factors, Disease Status, and Incident Events in a General Healthcare Population. Am. J. Cardiol. 2010, 106, 963–968.eng
dcterms.referencesArici, M.;Walls, J. End-Stage Renal Disease, Atherosclerosis, and Cardiovascular Mortality: Is C-Reactive Protein the Missing Link? Kidney Int. 2001, 59, 407–414eng
dcterms.referencesLópez, R.O.; de Motta, E.E.; Carmona, A.; Montemayor, V.G.; Berdud, I.; Malo, A.M.; García, P.A. Correction of 25-OH-Vitamin D Deficiency Improves Control of Secondary Hyperparathyroidism and Reduces the Inflammation in Stable Haemodialysis Patients. Nefrologia 2018, 38, 41–47.eng
dcterms.referencesMatias, P.J.; Jorge, C.; Ferreira, C.; Borges, M.; Aires, I.; Amaral, T.; Gil, C.; Cortez, J.; Ferreira, A. Cholecalciferol Supplementation in Hemodialysis Patients: Effects on Mineral Metabolism, Inflammation, and Cardiac Dimension Parameters. Clin. J. Am. Soc. Nephrol. 2010, 5, 905–911.eng
dcterms.referencesBucharles, S.; Barberato, S.H.; Stinghen, A.; Gruber, B.; Piekala, L.; Dambiski, A.C.; Custodio, M.R.; Pecoits-Filho, R. Impact of Cholecalciferol Treatment on Biomarkers of Inflammation and Myocardial Structure in Hemodialysis Patients Without Hyperparathyroidism. J. Ren. Nutr. 2012, 22, 284–291.eng
dcterms.referencesAlborzi, P.; Patel, N.A.; Peterson, C.; Bills, J.E.; Bekele, D.M.; Bunaye, Z.; Light, R.P.; Agarwal, R. Paricalcitol Reduces Albuminuria and Inflammation in Chronic Kidney Disease: A Randomized Double-Blind Pilot Trial. Hypertens 2008, 52, 249–255eng
dcterms.referencesNavarro-Gonzalez, J.F.; Donate-Correa, J.; Méndez, M.L.; De Fuentes, M.M.; García-Pérez, J.; Mora-Fernández, C. Anti- Inflammatory Profile of Paricalcitol in Hemodialysis Patients: A Prospective, Open-Label, Pilot Study. J. Clin. Pharmacol. 2013, 53, 421–426.eng
dcterms.referencesNavarro-Gonzalez, J.F.; Donate-Correa, J.; Méndez, M.L.; De Fuentes, M.M.; García-Pérez, J.; Mora-Fernández, C. Anti- Inflammatory Profile of Paricalcitol in Hemodialysis Patients: A Prospective, Open-Label, Pilot Study. J. Clin. Pharmacol. 2013, 53, 421–426.eng
dcterms.referencesBlock, G.A.; Martin, K.J.; de Francisco, A.L.; Turner, S.A.; Avram, M.M.; Suranyi, M.G.; Hercz, G.; Cunningham, J.; Abu-Alfa, A.K.; Messa, P.; et al. Cinacalcet for Secondary Hyperparathyroidism in Patients Receiving Hemodialysis. N. Engl. J. Med. 2004, 350, 1516–1525. [eng
dcterms.referencesRaggi, P.; Chertow, G.M.; Torres, P.U.; Csiky, B.; Naso, A.; Nossuli, K.; Moustafa, M.; Goodman,W.G.; Lopez, N.; Downey, G.; et al. The ADVANCE study: A randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis. Nephrol. Dial. Transplant. 2010, 26, 1327–1339eng
dcterms.referencesParfrey, P.S.; Chertow, G.M.; Block, G.A.; Correa-Rotter, R.; Drüeke, T.B.; Floege, J.; Herzog, C.A.; London, G.M.; Mahaffey, K.W.; Moe, S.M.; et al. The Clinical Course of Treated Hyperparathyroidism among Patients Receiving Hemodialysis and the Effect of Cinacalcet: The Evolve Trial. J. Clin. Endocrinol. Metab. 2013, 98, 4834–4844eng
dcterms.referencesCunningham, J.; Block, G.A.; Chertow, G.M.; Cooper, K.; Evenepoel, P.; Iles, J.; Sun, Y.; Ureña-Torres, P.; Bushinsky, D.A. Etelcalcetide Is Effective at All Levels of Severity of Secondary Hyperparathyroidism in Hemodialysis Patients. Kidney Int. Rep. 2019, 4, 987–994.eng
dcterms.referencesShigematsu, T.; Fukagawa, M.; Yokoyama, K.; Akiba, T.; Fujii, A.; Odani, M.; Akizawa, T. Effects of the Intravenous Calcimimetic Etelcalcetide on Bone Turnover and Serum Fibroblast Growth Factor 23: Post Hoc Analysis of an Open-label Study. Clin. Ther. 2018, 40, 2099–2111.eng
dcterms.referencesYu, L.; Tomlinson, J.E.; Alexander, S.T.; Hensley, K.; Han, C.-Y.; Dwyer, D.; Stolina, M.; Dean, C.; Goodman, W.G.; Richards, W.G.; et al. Etelcalcetide, A Novel Calcimimetic, Prevents Vascular Calcification in A Rat Model of Renal Insufficiency with Secondary Hyperparathyroidism. Calcif. Tissue Int. 2017, 101, 641–653.eng
oaire.versioninfo:eu-repo/semantics/publishedVersionspa

Archivos

Bloque original
Mostrando 1 - 1 de 1
Miniatura
Nombre:
16_2022-GC_ART_Etelcalcetide and Paricalcitol.pdf
Tamaño:
878.33 KB
Formato:
Adobe Portable Document Format
Descripción:
PDF
Descargar
Bloque de licencias
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
license.txt
Tamaño:
381 B
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar

Colecciones

Artículos

Universidad Simón Bolívar: Todos los derechos reservados / Sistema de biblioteca